“Our positive results in animals with ongoing disease raise the possibility that oral anti-CD3 antibodies might be an effective immunomodulatory therapy for SLE that could be easily and rapidly ...

The secondary cascade, although a normal physiological response, can contribute to ongoing neuroinflammation, oxidative ...

In a study published in Nature Neuroscience, researchers from Tiziana Life Sciences Ltd. and collaborators investigated the potential of nasal delivery of the CD3 foralumab to reduce neuroinflammation ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

This idea of splitting the anti-CD3 paratope ensures that each of the two drug components is completely inactive until both bind simultaneously to target antigens on the same tumor cell.

Context Therapeutics Inc.’s CNTX share price has dipped by 5.63%, which has investors questioning if this is right time to ...

It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

Its lead candidate is a fully human anti-CD3 monoclonal antibody for treating neurodegenerative and inflammatory diseases. It is called intranasal foralumab. The stock is up significantly so far ...

Tiziana(NASDAQ:TLSA) said the study demonstrated that nasal administration of foralumab, an anti-CD3 monoclonal antibody, ...

Immunotherapy. 2011;3(11):1303-1306. As discussed above, the proof-of-principle studies using both anti-CD3 antibodies (teplizumab and otelixizumab) showed effects on surrogate markers (C-peptide ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...